IP Library Granted Patent US 11,970,718
Granted Patent B2
US 11,970,718 · App. 17/146,902 · Granted Apr 30, 2024

Nucleic acid loaded extracellular vesicles

Inventors: Harvey Lodish (Brookline, MA); Ronne Yeo (Singapore, SG); Waqas Muhammad Usman (Kowloon, HK); Tenzin Gocha (Singapore, SG)
Assignee: Carmine Therapeutics Pte. Ltd.
C12N9/16A61K9/1271A61K35/18A61K48/0058A61K48/0091B82Y5/00C12N15/113C12N15/88C12N2310/14C12N2310/532C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,970,718
App. No.
17/146,902
Granted
Apr 30, 2024
Kind
B2
Abstract

An extracellular vesicle loaded with a nucleic acid cargo and method for preparing the loaded vesicle is disclosed.

Claims (33)

1. A preparation comprising a population of red blood cell extracellular vesicles (RBCEVs) loaded with a DNA cargo and a cationic reagent, wherein:

the RBCEVs have a size between 50 nm and 1,000 nm in diameter,

the DNA cargo has a length between 2,000 bases and 40,000 bases;

the cationic reagent complexes with the DNA cargo and is a polyethylenimine (PEI) reagent

and further wherein the preparation is characterized in that:

when the preparation is contacted with recipient mammalian cells, it is more effective at transfecting the mammalian cells with the DNA cargo than is an otherwise comparable reference preparation loaded by electroporation.

2. The preparation of claim 1 characterized in that, when contacted with recipient mammalian cells, it achieves transfection of more than 50% of the mammalian cells.

3. The preparation of claim 1 characterized in that it is at least twice as effective at transfecting the mammalian cells than is the reference preparation.

4. The preparation of claim 1 , further characterized in that, when contacted with recipient mammalian cells, it transfects more cells than does an otherwise comparable reference preparation loaded with an RNA cargo, rather than the DNA cargo, and the cationic reagent.

5. The preparation of claim 1 , wherein the DNA cargo is single-stranded (ssDNA).

6. The preparation of claim 1 , wherein the DNA cargo is double-stranded (dsDNA) and has a length between 1,000 base pairs and 20,000 base pairs.

7. The preparation of claim 1 , wherein the DNA cargo is an expression vector comprising a transgene encoding a protein or peptide.

8. The preparation of claim 1 , wherein the DNA cargo is circular.

9. The preparation of claim 1 , wherein the DNA cargo is a minicircle or plasmid.

10. The preparation of claim 1 , wherein the DNA cargo is linear.

11. The preparation of claim 1 , wherein the DNA cargo is loaded in the lumen of the RBCEVs.

12. The preparation of claim 1 , wherein the RBCEVs are derived or obtained from mammalian red blood cells.

13. The preparation of claim 1 , wherein the RBCEVs are isolated from a sample of human red blood cells.

14. The preparation of claim 1 , wherein each RBCEV within the population is loaded with an average of at least 1.0 copy number of the DNA cargo, at least 2.0 copy numbers of the DNA cargo, at least 3.0 copy numbers of the DNA cargo, or at least 4.0 copy numbers of the DNA cargo.

15. The preparation of claim 1 , wherein the PEI reagent is a linear polyethylenimine hydrochloride (LPH) having a molecular weight of 25,000 Da or 40,000 Da.

16. A method of loading a population of RBCEVs with a DNA cargo,

which method comprises steps of:

contacting the population of RBCEVs with a cationic reagent and the DNA cargo for a period of time sufficient for the DNA cargo to be loaded into RBCEVs of the population so that a loaded preparation is prepared,

wherein the RBCEVs have a size between 50 nm and 1,000 nm in diameter;

the DNA cargo has a length between 2,000 bases and 40,000 bases;

the cationic reagent complexes with the DNA cargo and is a polyethylenimine (PEI) reagent; and further wherein the loaded preparation is characterized in that,

when contacted with recipient mammalian cells, it is more effective at transfecting the mammalian cells with the DNA cargo than is an otherwise comparable reference preparation loaded by electroporation.

17. The method of claim 16 , wherein the RBCEVs have a size between 100 nm and 300 nm in diameter.

18. The method of claim 16 , wherein the loaded preparation is characterized in that it is at least twice as effective at transfecting the mammalian cells than is the reference preparation.

19. The method of claim 16 , wherein the loaded preparation is characterized in that, when contacted with recipient mammalian cells, it achieves transfection of more than 50% of the mammalian cells.

20. The method of claim 16 , wherein the loaded preparation is characterized in that, when contacted with recipient mammalian cells, it transfects more cells than does an otherwise comparable reference preparation loaded with an RNA cargo, rather than the DNA cargo, and the cationic reagent.

21. The method of claim 16 , wherein the polyethylenimine (PEI) reagent is a linear polyethylenimine hydrochloride.

22. The preparation of claim 1 , wherein the RBCEVs have a size between 100 nm and 300 nm in diameter.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2021
From: LODISH, HARVEY; YEO, RONNE; USMAN, WAQAS MUHAMMAD; GOCHA, TENZIN
To: CARMINE THERAPEUTICS PTE. LTD.
Reel/Frame 056943/0074 →
Continuity (3)
Provisional Application 62981880 · Feb 26, 2020
Provisional Application 62960569 · Jan 13, 2020
Related Publication 20210214217A1 · Jul 15, 2021